Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

ClinicalTrials.gov ID: NCT07555938

Public ClinicalTrials.gov record NCT07555938. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Study identification

NCT ID: NCT07555938
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 380 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 23, 2026 (Actual)
Primary completion: Oct 31, 2028 (Estimated)
Completion: Jan 31, 2033 (Estimated)
Last update posted: Oct 13, 2026

2026 – 2033

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010-3012	Recruiting
City of Hope - Lennar Foundation Cancer Center	Irvine	California	92618	Recruiting
Yale University	New Haven	Connecticut	06510	Recruiting
MedStar Washington Hospital Center MedStar Georgetown Cancer Institute	Washington D.C.	District of Columbia	20010	Recruiting
Emory University Hospital Midtown	Atlanta	Georgia	30308	Recruiting
Novant Health Cancer Institute	Charlotte	North Carolina	28215	Recruiting
Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists	Winston-Salem	North Carolina	27103	Recruiting
TriHealth Cancer and Blood Institute	Cincinnati	Ohio	45220	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030-4009	Recruiting
West Virginia University	Morgantown	West Virginia	26506	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07555938, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2026 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07555938 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →